Ongoing Trials
Are you a healthy male or female aged 18-77?
Have you ever wondered how new pharmaceutical products reach the market?
Would you like to be part of that development process and do something good today?
You will even receive payment for the time you give us during your participation.
- Who we are
Richmond Pharmacology conducts medical research to help develop new medicines. Our 2 research units, based in London at St George’s University Hospital and Croydon University Hospital, provide you with the safest and most comfortable facilities. Richmond Pharmacology works closely with Hospital Consultants, Research Physicians, and Clinicians ensuring the research we conduct is meaningful, ethical, and safe.
- What is this all about?
Chronic inflammation is most appropriately defined in terms of the process, in which continuing inflammation and attempted tissue healing by repair occur simultaneously. Chronic inflammation results in a variety of diseases, depending on the location of and trigger for the inflammation. These diseases include asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA) and psoriasis but there are many other diseases and disorders caused by chronic inflammation.
Richmond Pharmacology is conducting a clinical trial for a new experimental drug called FX125L. FX125L is an anti-inflammatory agent being developed for the treatment of chronic inflammatory diseases such as asthma, COPD, RA and psoriasis. It is anticipated that FX125L may be more effective and have fewer side effects compared to the current marketed drugs.
This is the first time FX125L will be given to patients with chronic inflammation. The purpose of this study, therefore, is to examine the impact of treatment with such an agent in patients with a range of different diseases that share a chronic inflammatory component. The purpose of this study is also to collect information on markers which will help us to plan future research studies, to further test the effect of this compound.
The trial is being conducted at Richmond Pharmacology Ltd only.
- Who is suitable for this study?
To qualify for participation you need to:
- Be aged between 18 and 77 years (inclusive) at screening
- Have a documented diagnosis of one of the following four conditions: asthma, COPD, RA or psoriasis (with a confirmed medical history available from your GP).
- Have a body mass index (BMI) between ≥18.0 and ≤35.0 kg/m2 (inclusive). Your BMI is calculated using the formula: weight (in kilograms) divided by height (in metres) squared).
- If you are female, have a negative pregnancy test at screening and on Day -1.
- Females of child-bearing potential must be using an adequate and medically acceptable method of contraception;
Acceptable methods include:
- Use an effective method of birth control (e.g., oral contraceptives combined with another method of birth control, intrauterine device, double-barrier method [e.g., condoms, diaphragm or cervical cap with spermicidal foam, cream or gel], or male partner sterilisation) before enrolment until the follow-up visit. All patients, whether they complete the study or not, will be requested to use an effective method of birth control for 90 days after their last dose
- Be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation or otherwise be incapable of pregnancy)
- Be abstinent when this is in line with the preferred and usual lifestyle of the subject; periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception, or
- Be postmenopausal (for at least 1 year); post-menopausal patients with FSH ≤40 mIU/mL must use an effective method of birth control
- Male patients must agree not to donate sperm, and to take appropriate precautions to avoid fathering a child, throughout the study and until 90 days after the end of treatment.
- What will happen?
This study is being conducted at our research facility at Croydon University Hospital in London. If you are interested in taking part you will need to contact us to register your interest.
If you successfully pass the telephone screening you will be invited to our facility where you will undergo a screening examination. This is vital to ensure it is safe for you to take part in the trial. You will be required to attend a screening visit 14 to 28 days before the start of the study. If you pass the screening visit you will be invited to take part in the study.
- Study Participation
- What’s in it for you?
Apart from doing something good, we will also compensate you for your time in the form of a monetary payment.
You will receive £560 your time on completion of the study, once follow-up results are confirmed, checked and deemed complete by the study doctor. You will be paid an additional bonus of £280 subject to your satisfactory compliance with the documents provided before study commencement (Volunteer Information sheet and Informed Consent, the Richmond Pharmacology Volunteer Charter and all other unit regulations).
The total amount that you could be paid for study participation is £840. You will also be compensated for your travel expenses.*
* You will receive travel expenses up to a value of £150 if you are included in the study and following the delivery of valid receipts for travel relating to your participation in this study. All study related travel expenses within the limit of £150 will be paid in conjunction with your study payment following the completion of your participation in the trial.
- Want to find out more?
Or
Call us free on 0800 085 64 64 and speak to a member of our Volunteer Recruitment Team.
A detailed information sheet is available on request.
Ref: FXT_Oct 2011
C11067_eDM and web story_version 1_24 10 11.docx
Register now for more details!
Are you a healthy female aged 18-45?
- What is this all about?
Although current drugs used to treat for HCMV are effective, the drugs are also toxic at higher doses and may affect kidney and bone marrow function in some patients. The sponsor company for this study is developing a new drug called Letermovir and it is anticipated that it will be less toxic than current treatments. Letermovir may interact with other drugs such as Digoxin (Lanoxin®) which may also be given to severely ill patients (for example those suffering from heart disease) and increase its levels in the blood which may cause toxic side effects.
The aim of this part of the clinical trial is to identify the safest dose that can be given to patients by testing the drug in increasing doses (relative to previous trials) in healthy volunteers. In previous trials it has been found that higher doses than those tested may be required in order to treat patients. Therefore, in this trial we will give higher doses compared to the previous doses that have been given to patients, in order to identify the highest well-tolerated dose that can be given safely to patients.
We may also want to collect additional data regarding how food affects heart function as part of this trial so we may perform some intensive ECGs (electrical heart recordings) before you receive the trial medication.
The trial is being conducted at Richmond Pharmacology Ltd only.
- Who is suitable for this study?
To qualify for participation you need to:
- Be a healthy female of any ethnic origin (a minimum of 70% will be Caucasian indigenous to Europe for each cohort) aged between 18 and 45 years (inclusive) at screening
- Have a regular menstrual cycle with a length between 24 – 32 days
- Have a body mass index (BMI) between ≥18.0 and ≤28.0 kg/m2 (inclusive) at screening, and a body weight of at least 60 kg.
- Have a negative pregnancy test at screening and on Day -1.
- Be able to communicate well with the Investigator in English, and to understand and fully comply with the requirements of the trial.
- If you are a smoker, you must not have smoked more than 10 cigarettes or
equivalent amount of tobacco per day at screening or during the
screening period.
- Agree to use acceptable methods of contraception.
Female volunteers of childbearing potential must use medically acceptable methods of contraception (non-hormonal methods) from 4 weeks before first admission until three months following administration of the last dose of trial medication.
Acceptable methods include:
- A documented placement of an intrauterine device (IUD) or intrauterine system (IUS) and the use of a barrier method {condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicidal foam/gel/film/cream/suppository};
- Documented tubal ligation (female sterilisation). In addition, a barrier method {condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicidal foam/gel/film/cream/suppository} should also be used;
- Double barrier method: Condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository;
- What will happen?
This study is being conducted at our research facility at Croydon University Hospital in London. If you are interested in taking part you will need to contact us to register your interest.
If you successfully pass the telephone screening you will be invited to our facility where you will undergo a screening examination. This is vital to ensure it is safe for you to take part in the trial. You will be required to attend a screening visit 2 to 21 days before the start of the study. If you pass the screening visit you will be invited to take part in the study.
PART A Cohort 5
Participation for this part of the trial requires you to stay at our clinical unit at Croydon University Hospital for 1 residential stay lasting 15 days (Visit 2). You will also be required to attend a follow up visit 7-14 days (Visit 3) after you are discharged from the unit. Your participation in this study will last approximately 48 days including the screening visit (Visit 1) within 2-14 days before the first dose of the study drug.
Study dates for this part of the trial are as follows:
Group 1
Admissions: 08/02/2012
Dismissal: 23/02/2012
Follow up: 02/03/2012
Group 2
Admissions: 09/02/2012
Dismissal: 24/02/2012
Follow up: 02/03/2012
- What’s in it for you?
You will receive £1,100 your time on completion of the study, once follow-up results are confirmed, checked and deemed complete by the study doctor. You will be paid an additional bonus of £540 subject to your satisfactory compliance with the documents provided before study commencement (Volunteer Information sheet and Informed Consent, the Richmond Pharmacology Volunteer Charter and all other unit regulations).
The total amount that you could be paid for participation is £1,640. This payment includes all travel expenses.
- Want to find out more?
Or
Call us free on 0800 085 64 64 and speak to a member of our Volunteer Recruitment Team.
A detailed information sheet is available on request.
Ref: AC 1_Sep 2011 (PART A)
11061_eDM and web story_version 2_PART A_19 10 11.docx
Register now for more details!
Recommend a Friend
If you are not selected to take part in a study you could still earn money. Recommend a friend successfully to take part in this study, and once they have completed the study you could earn anything from £90 to £350!
Register now for more details!
Please upgrade
your Flash Player
St George's and Mayday Hospitals
could earn between £90 - £350
also receive £5 for travel expenses
Please upgrade
your Flash Player
